Patent · US Active

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors

US9809590B2 · kind B2 · utility

1Cited by
1References
29Claims
0Family size

Assignee

Inventors

Key dates

Filing dateSep 18, 2015
Grant dateNov 7, 2017
Priority date—
Expiry dateSep 25, 2035

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P43/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.